Diagnóstico y tratamiento de la tuberculosis

Lamentablemente, las novedades en tuberculosis (TB) se producen de forma lenta, demasiado lenta. No obstante, han pasado bastantes anos desde las ultimas Normativas de la Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) sobre el diagnostico y el tratamiento de la TB, y durante este periodo no solo se han producido avances en el diagnostico y el tratamiento, especialmente en el campo del diagnostico, sino que ademas hemos asistido a un importante cambio demografico en Espana motivado por el incremento de la inmigracion. En la actualidad el 10% del total de la poblacion espanola no ha nacido en el pais y el 30% de los casos de TB corresponden a pacientes inmigrantes. Por todo ello, nos ha parecido oportuno y necesario revisar nuestras guias para actualizarlas y adaptarlas a la presente configuracion social espanola. En un esfuerzo de simplificacion hemos decidido agrupar en una sola las normativas previas sobre diagnostico y tratamiento de la TB. Para la elaboracion de la presente guia hemos tenido en cuenta la evidencia cientifica disponible. El grado de recomendacion se clasifica como A, B, C y D. El grado A significa que la evidencia cientifica en que se basa es buena o muy buena (estudios de nivel 1); el B, que es razonablemente buena (estudios de nivel 2); el C, que es escasa (series y casos), y el D, que asienta en opiniones de expertos y consensos. Agradecemos al Comite Cientifico de la SEPAR la deferencia y la confianza que han otorgado al grupo de expertos para llevar a cabo la nueva Normativa y esperamos y deseamos que sea de utilidad para mejorar el control de la TB. DIAGNOSTICO DE LA INFECCION TUBERCULOSA

[1]  Neel R Gandhi,et al.  Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa , 2006, The Lancet.

[2]  A. Lacoma,et al.  Comparison of Two Commercially Available Gamma Interferon Blood Tests for Immunodiagnosis of Tuberculosis , 2007, Clinical and Vaccine Immunology.

[3]  A. Hill,et al.  Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. , 2001, The Journal of infectious diseases.

[4]  T. Sterling,et al.  American Thoracic Society Documents An Official ATS Statement : Hepatotoxicity of Antituberculosis Therapy , 2006 .

[5]  V. Sypsa,et al.  The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  L. Leibovici,et al.  Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. , 2006, The Cochrane database of systematic reviews.

[7]  S. Juncosa,et al.  Tuberculin reactivity in Bacillus Calmette-Guérin vaccinated subjects. , 1996, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  E. M. Moragón,et al.  Enfermedad pulmonar por micobacterias ambientales oportunistas en pacientes sin infección por el virus de la inmunodefíciencia humana. Factores de riesgo, clínica, diagnóstico y evolución , 1996 .

[9]  Grupo de Trabajo de la Separ.  Recomendaciones separ. normativa sobre la prevención de la tuberculosis , 2002 .

[10]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[11]  Elsie Lee,et al.  Evolution and current use of the tuberculin test. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Jeudy,et al.  Acute Lung Infections in Normal and Immunocompromised Hosts , 2006, Radiologic Clinics of North America.

[13]  I. Adetifa,et al.  Treatment of latent tuberculosis infection in HIV infected persons. , 2010, The Cochrane database of systematic reviews.

[14]  L. Clancy,et al.  Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. , 1999, The European respiratory journal.

[15]  J. Sauret,et al.  Tratamiento y retratamiento de la tuberculosis , 1996 .

[16]  Talleres de,et al.  Prevención y control de las tuberculosis importadas , 2003 .

[17]  T. British,et al.  BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment , 2005, Thorax.

[18]  J. Caylà,et al.  Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. , 1998, The European respiratory journal.

[19]  J Lees,et al.  European framework for tuberculosis control and elimination in countries with a low incidence , 2002, European Respiratory Journal.

[20]  Juan Ruiz-Manzano,et al.  Prueba de la tuberculina: ¿es la hora del cambio? , 2006 .

[21]  P. Godoy,et al.  La respuesta a la prueba de la tuberculina en enfermos tuberculosos , 2002 .

[22]  J. Caminero.  Management of multidrug-resistant tuberculosis and patients in retreatment , 2005, European Respiratory Journal.

[23]  S. Kim.  Drug-susceptibility testing in tuberculosis: methods and reliability of results , 2005, European Respiratory Journal.

[24]  C. Barrero,et al.  Control y supervisión del enfermo tuberculoso , 2001 .

[25]  J. Collazos.  Chest radiographic findings in patients with tuberculosis with recent or remote infection. , 1997, American journal of respiratory and critical care medicine.

[26]  J. A. C. Luna,et al.  Diagnóstico de la tuberculosis , 1996 .

[27]  P. Fujiwara,et al.  Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals? , 2005, European Respiratory Journal.

[28]  J. Burzynski,et al.  Clinical and radiographic correlates of primary and reactivation tuberculosis: a molecular epidemiology study. , 2005, JAMA.

[29]  P. Clevenbergh,et al.  Management of adults living with HIV/AIDS in low-income, high-burden settings, with special reference to persons with tuberculosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[30]  J. Caylà,et al.  Proposing indicators for evaluation of tuberculosis control programmes in large cities based on the experience of Barcelona. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[31]  D. Cook,et al.  Isoniazid for preventing tuberculosis in non-HIV infected persons. , 1999, The Cochrane database of systematic reviews.

[32]  J. Palomino,et al.  Tuberculosis 2007; from basic science to patient care , 2007 .

[33]  R. Huebner,et al.  The tuberculin skin test. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Charles F. Lacy,et al.  Drug Information Handbook , 1998 .

[35]  G. Woods,et al.  The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial. , 2000, JAMA.

[36]  J. Burzynski,et al.  Clinical and Radiographic Correlates of Primary and Reactivation Tuberculosis , 2006 .

[37]  L. Lambert,et al.  Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[38]  R. Horsburgh,et al.  Priorities for the treatment of latent tuberculosis infection in the United States. , 2004, The New England journal of medicine.

[39]  D. Menzies.  Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. , 1999, American journal of respiratory and critical care medicine.

[40]  Luca Richeldi,et al.  An update on the diagnosis of tuberculosis infection. , 2006, American journal of respiratory and critical care medicine.

[41]  Sonya S. Shin,et al.  Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru , 2006, Thorax.

[42]  M. Pai,et al.  Meta-analysis: New Tests for the Diagnosis of Latent Tuberculosis Infection: Areas of Uncertainty and Recommendations for Research , 2007, Annals of Internal Medicine.

[43]  C. Doré,et al.  Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. , 2003, American journal of respiratory and critical care medicine.

[44]  P. Hopewell,et al.  Clinical practice. Latent tuberculosis infection. , 2002, The New England journal of medicine.

[45]  P. Andersen,et al.  Specific immune-based diagnosis of tuberculosis , 2000, The Lancet.

[46]  L. Tanoue,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. , 2005, American journal of respiratory and critical care medicine.

[47]  J. Ena,et al.  Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  Keiji Fukuda,et al.  Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2002, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[49]  N. Müller,et al.  Tuberculosis in young adults and the elderly. A prospective comparison study. , 1994, Chest.